This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
TRAIN-2 was a randomized phase 3 treatment trial in patients with HER2-positive breast cancer evaluating two neoadjuvant chemotherapy approaches containing pertuzumab.
| Feature | TRAIN-2 |
|---|---|
| Condition | Breast Cancer; HER2 Positive |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | The Netherlands Cancer Institute |
| Status | Active, not recruiting |
2. Clinical Question
Population
Patients with HER2-positive breast cancer.
Intervention
PTC plus pertuzumab, or FEC-T plus pertuzumab followed by PTC plus pertuzumab.
Comparator
The randomized comparison between the two neoadjuvant chemotherapy strategies.
Primary question
To compare efficacy of six cycles of neoadjuvant PTC plus pertuzumab preceded by either three cycles of FEC-T plus pertuzumab or three cycles of PTC plus pertuzumab.
3. Trial Design
Arm 1
PTC + Pertuzumab
Arm 2
FEC-T + Pertuzumab followed by PTC + Pertuzumab
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Number of patients with pathological complete response | Compare efficacy of the two neoadjuvant treatment strategies in HER2-positive breast cancer. | At week 30 |
5. Planned Analysis
The registry identifies pathological complete response as the primary endpoint. Pathological complete response is a binary endpoint, meaning the analysis would typically compare the proportion of patients achieving the endpoint between randomized groups using an appropriate comparative statistical test and estimate of treatment difference.
The ClinicalTrials.gov record does not report posted statistical analyses or trial results.
6. Statistical Methodology
The randomized parallel-group design supports comparison of outcomes between treatment strategies while preserving the benefits of random allocation. The primary endpoint is an event proportion rather than a time-to-event outcome.
Binary endpoint framework
A common analysis approach for a binary response endpoint compares:
Response proportion = patients achieving pathological complete response ÷ analyzed patients
The interpretation focuses on the difference between randomized groups and the uncertainty around that difference.
7. Statistical Methods Explained
Why is pathological complete response suitable as an endpoint?
Pathological complete response provides a direct assessment of treatment effect before surgery. It measures whether the treatment produced the predefined pathological outcome at the specified assessment time.
Why does randomization matter?
Randomization helps balance known and unknown patient characteristics between treatment groups, allowing differences in outcomes to be attributed more directly to the assigned strategies.
What does a proportion comparison estimate?
A comparison of proportions estimates whether the frequency of pathological complete response differs between groups. Confidence intervals describe uncertainty around the estimated difference.
Why is the analysis not interpreted like survival analysis?
The registry endpoint is measured at a fixed time point rather than as time until an event occurs. Methods such as Kaplan-Meier estimation and Cox proportional-hazards models are designed for time-to-event outcomes and are not the primary framework for this endpoint.
8. Limitations
- The registry does not report posted statistical analyses or numerical efficacy results.
- The primary endpoint is assessed at a specified time point, so interpretation depends on the endpoint definition and assessment process.
- Without posted results, the magnitude and precision of treatment differences cannot be evaluated.
9. Why This Trial Matters Statistically
| Concept | How it appears in TRAIN-2 |
|---|---|
| Randomization | Patients were assigned in a randomized parallel design. |
| Binary endpoint analysis | Primary endpoint is pathological complete response at week 30. |
| Comparative effectiveness | Two neoadjuvant strategies are evaluated. |
| Clinical trial design | Phase 3 treatment comparison. |
10. Related Tutorials
No related tutorial cards are listed for this trial.
11. Related Calculators
No related calculator cards are listed for this trial.